JAGX
Jaguar Health, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.64
−19.61%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$2.00
From 52W high−99.84%
Volume323124.00
Market cap$3.81M
P/E (TTM)—
P/S (TTM)0.1x
Div yield—
Key dataOct 30, 2026
Open
$2.00
From 52W high
−99.84%
Volume
323124.00
Market cap
$3.81M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
39.8
MomentumView details →
1D Return
−19.61%
YTD Return
−99.66%
SummaryUpdated Jun 1, 2026
Jaguar Health, Inc. (NASDAQ:JAGX) is a commercial-stage pharmaceutical company founded in 2013 and headquartered in San Francisco, California. The company went public in May 2015 and focuses on developing prescription medicines for gastrointestinal distress, particularly chronic and debilitating diarrhea conditions in both humans and animals. Jaguar Health operates through two primary segments: Human Health and Animal Health, with its lead commercial product being <b>Mytesi</b>, an FDA-approved treatment for HIV-related diarrhea.
Similar companies
Latest newsMore news →
Jaguar Health announced that its family company Napo Pharmaceuticals, Inc. has provided crofelemer to an infant with a GUCY2C mutation for several weeks, with treatment reportedly reducing daily and weekly parenteral support needs and being well tolerated.9d agoJaguar Health reminded shareholders that October 13, 2026, is the record date for its previously declared special stock dividend to holders of common stock and certain outstanding warrants.17d agoJaguar Health's Board of Directors declared a special stock dividend of Series R Convertible Preferred Stock to holders of Jaguar common stock and certain outstanding warrants as of the October 13, 2026 record date.28d ago